Genelux Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Genelux Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both fell in each of the last 3 years. Less steady than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-26.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 62% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +244%In 3 years sales changed by -100% while total assets changed by +244%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-59.2×Operating cash was negative last year, while some debt falls due within a year.
Lower than 76% of Healthcare companies in United States.
Cash Cushion Ratio
+14%Cash, after subtracting all debt, equals 14% of its market value (net cash).
Higher than 57% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Genelux Corporation made a loss over the last year. Genelux Corporation owes $0.39 for every $1 it owns. Genelux Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossGenelux Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
5.56The share price is 5.56 times Genelux Corporation's book value per share, higher than 75% of Healthcare companies in United States.
Market cap
$90 MThe total market value of all of Genelux Corporation's shares at today's price (share price × number of shares), smaller than 67% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$16 MWhat Genelux Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.36Net worth divided by the number of shares. The share price of $1.98 is 5.6 times this, which is the P/B above.
Return on equity (ROE)
-177.9%Genelux Corporation lost 177.9% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
Owes vs Owns
0.39×Genelux Corporation owes $0.39 for every $1 it owns (low), lower than 53% of Healthcare companies in United States.
Dividend yield
NoneGenelux Corporation does not currently pay a dividend.
Revenue growth
+0%Revenue rose 0% in the year to Dec 2025, and shrank 91% a year on average over 3 years.
Profit growth
LossGenelux Corporation made a loss in each of the last two years.
Profit margin
-401812.5%Genelux Corporation lost $401812 for every $100 of revenue.
Cash vs debt
Net cashGenelux Corporation held $13 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Genelux Corporation: $90 M ÷ $16 M (30 Jun 2026) = 5.6.
What is Genelux Corporation's return on equity?
Genelux Corporation lost 177.9% of its shareholders' money over the last year, lower than 82% of Healthcare companies in United States.
How much does Genelux Corporation owe compared with what it owns?
Genelux Corporation owes $0.39 for every $1 it owns (low), lower than 53% of Healthcare companies in United States.
Does Genelux Corporation pay a dividend?
No. Genelux Corporation does not currently pay a dividend.
Is Genelux Corporation's revenue growing?
Revenue rose 0% in the year to Dec 2025, and shrank 91% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.